A synthetic glucagon-like peptide-1 analog with improved plasma stability

Journal of Endocrinology

Volumn 159, Issue 1, 1998, Pages 93-102

  Ritzel, U ^a   Leonhardt, U ^a   Ottleben, M ^a   Ruhmann A ^b   Eckart, K ^b   Spiess, J ^b   Ramadori, G ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; INSULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DIABETES MELLITUS; HORMONE RELEASE; HUMAN; INSULIN RELEASE; NEUROENDOCRINOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PEPTIDE ANALYSIS; PLASMA; PRIORITY JOURNAL; RAT;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; GLUCOSE; HUMANS; INSULIN; MALE; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; RATS; RATS, WISTAR; RECEPTORS, GLUCAGON; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0031720650     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1590093     Document Type: Article

References (42)

1. Addhorst K, Hedegaard DB, Knudsen LB & Kirk O 1994 Structure-activity studies of glucagon-like peptide-1. Journal of Biological Chemistry 9 6275-6278.
2. Ahmad S, Wang L & Ward E 1992 Dipeptidyl(amino)peptidase IV and aminopeptidase M metabolize circulating substance P in vivo. Journal of Pharmacolagy and Experimental Therapeutics 260 1257-1261.
3. Ashcroft SJH, Hammonds P & Harrison DE 1986 Insulin secretory responses of a clonal cell line of simian virus 40-transformed B cells. Diabetologia 29 727-733.
4. Boulanger L, Roughly P & Gaudreau P 1992 Catabolism of rat growth hormone-releasing factor (1-29) amide in rat serum and liver. Peptides 13 681-689.
5. Buckley DI & Lundquist P 1992 Analysis of the degradation of insulinotropin [GLP-1(7-37)] in human plasma and production of degradation resistant analogs. Regulatory Peptides 40 117.
6. Cooper TG 1981 Radioimniunoassay Markierungen. In Biochemische Arbeitsmethoden pp 281-284. Berlin, New York: Walter de Gruyter.
7. Deacon CF, Johnsen AH & Holst JJ 1995 Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. Journal of Clinical Endocrinology and Metabolism 80 952-957.
8. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O & Holst JJ 1998 Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabctolagia 41 271-278.
9. Dillon JS, Tanizawa Y, Wheeler MB, Leng X-H, Ligon BB, Rabin DU, Yoo-Warren H, Permutt MA & Boyd AE 1993 Cloning and functional expression of the human glucagon-like peptide-1 (GLP-1) receptor. Endocrinology 133 1907-1910.
10. D'Alessio DA, Fujimoto WY & Ensinck JW 1989 Effects of glucagon like peptide-1 (7-36) on release of insulin, glucagon, and somatostatin by rat pancreas islet cell monolayer cultures. Diabetes 38 1534-1538.
11. D'Alessio D, Thirlby R, Laschansky E, Zebroski H & Ensinck J 1993 Response of tGLP-1 to nutrients in humans. Digestion 54 377-379.
12. Fehmann H-C, Göke R, Göke B, Böchle R, Wagner B & Arnold R 1991 Priming effect of glucagon-like peptide-1 (7-36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas. Biochimica et Biophysica Acta 1091 356-363.
13. Frohmann LA, Downs TR, Heimer EP & Felix AM 1989 Dipeptidyl peptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. Journal of Clinical Investigation 83 1533-1540.
14. Göke R, Richter G, Kolligs F, Fehmann HC, Arnold R & Göke B 1993a How do individual meal constituents influence the release of GLP-1 in humans? Digestion 54 380.
15. Göke R, Fehmann H-C, Linn T, Schmidt H, Krause M, Eng J & Göke B 1993d Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide-1-(7-36)-amide receptor of insulin-secreting β-cells. Journal of Biological Clemistry 268 19650-19655.
16. Gutniak M, Ørskov C, Holst JJ, Ahren D & Effendic S 1992 Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. New England Journal of Medicine 326 1316-1322.
17. Gutniak MK, Linde B & Efendic S 1993 Subcutaneous injection of glucagon-like insulinotropic peptide reduces postprandial glycaemia in non-insulin-dependent diabetes. Digestion 54 389-390.
18. Hendrick GK, Gjinovici A, Baxter LA, Mojsov S, Wollheim CB, Habener JF & Weir GC 1993 Glucagon-like peptide-1 (7-36) suppresses hyperglycemia in rats. Metabolism 42 1-6.
19. Herrmann C, Göke R, Richter G, Fehmann H-C, Arnold R & Göke B 1995 Glucagon-like peptide-1 and glucose-dependent insulinreleasing polypeptide plasma levels in response to nutrients. Digestion 56 117-126.
20. Hill RS & Boyd AE 1985 Perifusion of a clonal cell line of simian virus 40-transformed beta cells. Diabetes 34 115-120.
21. Kieffer TJ, McIntosh HS & Pederson RA 1995 Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136 3585-3596.
22. Kolligs F, Fehimnn H-C, Göke R & Göke B 1995 Reduction of the incretin effect in rats by the glucagon-likc peptide 1 receptor antagonist exendin(9-39)amide. Diabetes 44 16-19.
23. Loijda Z 1979 Studies on dipeptidyl(amino)peptidase IV. II. Blood vessels. Histochemistry 59 153-166.
24. Lu M, Wheeler MB, Leng X-H & Boyd AE 1993 The roles of cAMP levels and free cytosolic calcium concentrations in the insulin secretion and insulin gene expression stimulated by glucagon-like peptide 1. Digestion 54 349-351.
25. McCaughan GW, Wickson JE, Cheswick PF & Gorrel MD 1990 Identification of the bile cannicular cell surface molecule GP110 as the ectopeptidase dipeptidyl peptidase IV, an analysis by tissue distribution, purification and N-terminal amino acid sequence. Hepatobgy 11 534-544.
26. Matsumura T, Itoh H, Watanabe N, Oda Y, Tanaka M, Naniba M, Kono N, Matsuyama T, Komatsu R & Matsuzawa Y 1992 Glucagon-like peptide-1 (7-36) amide suppresses glucagon secretion and decreases cyclic AMP concentration in cultured In-R1-G9 cells. Biochemical and Biophysical Research Communications 186 503-508.
27. Mentlein R, Heymann E, Scholz W, Feller AC & Flad HD 1984 Dipeptidyl peptidase IV is a new surface marker for a subpopulation of human T-lymphocytes. Cell Immunology 89 11-19.
28. Mentlein R, Gallwitz B & Schmidt WE 1993 Dipeptidyl-peptidase IV hydrolyzes gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. European Journal of Biochemistry 214 829-835.
29. Mojsov S 1992 Structural requirements for biological activity of glucagon-like peptide-1. International Journal of Peptide Protein Research 40 333-343.
30. Mojsov S, Weir GC & Habener JF 1987 Insulinotropin: glucagon-like peptide-1 (7-37), coencoded in the glucagon gene is a potent stimulator of insulin release in the perfused pancreas. Journal of Clinical Investigation 79 616-619.
31. Morgan L, Elliott R, Tredger J, Nightingale J & Marks V 1993 GLP-1 secretion in response to nutrients in man. Digestion 54 374-376.
32. Nauk MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R & Creutzfeldt W 1993a Preserved incretin activity of glucagon-like peptide 1 (7-36) amide but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. Journal of Clinical Investigation 91 301-307.
33. Nauk MA, Kleine N, Ørskov C, Holst JJ, Willms B & Creutzfeldt W 1993b Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36) amide in type 2 (non-insulin-dependent) diabetic patients. Digestion 54 389.
34. Nausch I & Heymann E 1985 Substance P in human plasma is degraded by dipeptidyl peptidase IV, not by cholinesterase. Journal of Neurochemistry 44 1354-1357.
35. Ørskov C 1992 Glucagon-like peptide-1, a new hormone of the enteroinsular axis. Diabetologia 35 701-711.
36. Ørskov C, Holst JJ & Nielsen OV 1988 Effect of truncated glucagon-like peptide-1 (proglucagon 78-107) on endocrine secretion from pig pancreas, antrum and stomach. Endocrinology 123 2009-2013.
37. Qualmann C, Nauck MA, Holst JJ. Ørskov C & Creutzfeldt W 1995 Insulinotropic actions of intravenous glucagon-like peptide 1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetologica 32 13-16.
38. Rahfeld J, Schutkowski M, Faust J, Neubert K, Barth A & Heins J 1991 Extended investigation of the substrate specificity of dipeptidyl peptidase IV from pig kidney. Biological Chemistry Hoppe-Seyler 372 313-318.
39. Thorens B 1992 Expression cloning of the pancreatic β cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proceedings of the National Academy of Sciences of the USA 89 8641-8645.
40. Thorens B & Waeber G 1993 Glucagon-like peptide-1 and the control of insulin secretion in the normal state and in NIDDM. Diabetes 42 1219-1225.
41. Wheeler MB, Lu M, Dillon JS, Leng X-H, Chen C & Boyd AE 1993d Functional expression of the rat glucagon-like peptide-1 receptor, evidence for coupling to both adenyl cyclase and phospholipase-C. Endocrinology 133 57-62.
42. Wheeler MB, Lu M, Dillon JS, Leng X-H & Boyd JS 1993b The rat glucagon-like peptide-1 receptor can couple to adenyl cyclase, phospholipase C and the free cytosolic calcium level. Digestion 54 348-349.